突变和代谢因素影响毒性和无毒性的相互作用 Aspergillus flavus
Szilvia Kovács1, Barbara Brendzsák1, Walter P Pfliegler2
1Central Laboratory of Agricultural and Food Products, Faculty of Agricultural and Food Sciences and Environmental Management, University of Debrecen, Böszörményi Str. 138, H-4032 Debrecen, Hungary.
Microorganisms
|February 27, 2026
概括
识别无氧化阿斯伯吉illus flavus菌株对生物控制至关重要. 这项研究揭示了基因突变和可扩散分子影响着亚毒素B1的产生和真菌相互作用,有助于食品安全工作.
科学领域:
- 农业科学 农业科学
- 菌类学 菌类学是指菌类学.
- 食品安全 食品安全
背景情况:
- 由Aspergillus flavus产生的阿弗拉托克辛B1 (AFB1) 引起了严重的食品安全问题.
- 在竞争性排斥中使用A. flavus的抗氧化菌株,以减少毒性种群和AFB1水平.
- 在可靠地识别抗氧化菌株和理解它们的竞争机制方面存在挑战.
研究的目的:
- 系统地分析A. flavus菌株的阿弗拉托克辛基因集群和AFB1生产.
- 为了确定基因和分子因素控制的氧化性和跨菌株相互作用.
- 改进识别抗氧化菌株的方法,以进行有效的生物控制.
主要方法:
- 在A. flavus菌株中分析了亚黄素基因集群和AFB1的产生.
- 研究关键的亚弗拉托克辛生物合成基因 (例如,aflL,aflLa,norA,verA,omtA) 的突变.
- 共同培养实验研究菌株相互作用和评估酸减少产品.
主要成果:
- 抗氧化菌株在生物合成基因中表现出内部损失和高影响突变,使PCR识别复杂化.
- AFB1的产生与子度相反.
- 菌株相互作用通过可扩散分子发生,导致共同文化的形态变化.
- 酸的新陈代谢使毒性菌株与无氧性菌株有区别.
结论:
- 遗传变异,包括内部损失和特定基因的突变,是对抗氧性性的关键.
- 扩散分子介于有毒性和无氧性A. flavus菌株之间的相互作用.
- 了解这些因素对于制定强有力的生物控制策略来防止亚毒素污染至关重要.
相关概念视频
Fungal Phylum Ascomycota
1.8K
Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
1.8K
Factors Affecting Drug Biotransformation: Biological
750
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
750
Drug toxicity: Idiosyncratic Reactions
64
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
64
Drug Toxicity: Risk factors
60
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
60
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
Mutagenicity and Carcinogenicity
2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K


